Cargando…

Abnormal Expression of N6-Methyladenosine RNA Methylation Regulator IGF2BP3 in Colon Cancer Predicts a Poor Prognosis

The value of insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3), an N6-methyladenosine (m6A) RNA methylation regulatory factor, in the prognosis of colon cancer was still unclear. High levels of IGF2BP3 were expressed in colon adenocarcinoma (COAD) samples and in human colon cancer tissue...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Tao, Zhang, Xuan, Xing, Lu, Pan, Dingguo, Liu, Ping, Ding, Rong, Yang, Renfang, Yang, Xudong, Li, Yunfeng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9170420/ https://www.ncbi.nlm.nih.gov/pubmed/35677634 http://dx.doi.org/10.1155/2022/5883101

Ejemplares similares

RNA N6-methyladenosine reader IGF2BP3 regulates cell cycle and angiogenesis in colon cancer
por: Yang, Zhou, et al.
Publicado: (2020)

IGF2BP2 regulates DANCR by serving as an N6-methyladenosine reader
por: Hu, Xiaoge, et al.
Publicado: (2019)

FLOT1, stabilized by WTAP/IGF2BP2 mediated N6-methyladenosine modification, predicts poor prognosis and promotes growth and invasion in gliomas
por: Song, Tao, et al.
Publicado: (2023)

Recognition of RNA N(6)-methyladenosine by IGF2BP Proteins Enhances mRNA Stability and Translation
por: Huang, Huilin, et al.
Publicado: (2018)

IGF2BP3 overexpression predicts poor prognosis and correlates with immune infiltration in bladder cancer
por: Huang, Wei, et al.
Publicado: (2023)

IGF2BP3 is an essential N(6)-methyladenosine biotarget for suppressing ferroptosis in lung adenocarcinoma cells
por: Xu, Xin, et al.
Publicado: (2022)

N(6)-methyladenosine (m(6)A) reader IGF2BP2 promotes gastric cancer progression via targeting SIRT1
por: Zhang, Zili, et al.
Publicado: (2022)

IGF2BP2 Regulates MALAT1 by Serving as an N6-Methyladenosine Reader to Promote NSCLC Proliferation
por: Han, Le, et al.
Publicado: (2022)

RNA N6-methyladenosine reader IGF2BP3 interacts with MYCN and facilitates neuroblastoma cell proliferation
por: Zhu, Kai, et al.
Publicado: (2023)

N(6)-methyladenosine reader IGF2BP3 as a prognostic Biomarker contribute to malignant progression of glioma
por: Zheng, Xin, et al.
Publicado: (2023)

N6-methyladenosine modified LINC00901 promotes pancreatic cancer progression through IGF2BP2/MYC axis
por: Peng, Wan-Xin, et al.
Publicado: (2022)

MYC-activated RNA N6-methyladenosine reader IGF2BP3 promotes cell proliferation and metastasis in nasopharyngeal carcinoma
por: Du, Mingyu, et al.
Publicado: (2022)

Multi-omics analysis of N6-methyladenosine reader IGF2BP3 as a promising biomarker in pan-cancer
por: Chen, Pin, et al.
Publicado: (2023)

IGF2BP3 promotes progression of gallbladder carcinoma by stabilizing KLK5 mRNA in N(6)-methyladenosine-dependent binding
por: Zhang, Junzhe, et al.
Publicado: (2022)

Targeting IGF2BP3 in Cancer
por: Liu, Xin, et al.
Publicado: (2023)

CircPTPRA blocks the recognition of RNA N(6)-methyladenosine through interacting with IGF2BP1 to suppress bladder cancer progression
por: Xie, Fei, et al.
Publicado: (2021)

Investigation of Igf-1, Igf-Bp3 and Igf-Bp5 levels in umbilical cord blood of infants with developmental dysplasia of the hip
por: DEMİREL, Esra, et al.
Publicado: (2023)

METTL3/IGF2BP3 axis inhibits tumor immune surveillance by upregulating N(6)-methyladenosine modification of PD-L1 mRNA in breast cancer
por: Wan, Weijun, et al.
Publicado: (2022)

RBM15 promotes hepatocellular carcinoma progression by regulating N6-methyladenosine modification of YES1 mRNA in an IGF2BP1-dependent manner
por: Cai, Xianlei, et al.
Publicado: (2021)

Correction: CircPTPRA blocks the recognition of RNA N(6)-methyladenosine through interacting with IGF2BP1 to suppress bladder cancer progression
por: Xie, Fei, et al.
Publicado: (2022)

N(6)-methyladenosine (m(6)A) reader IGF2BP1 facilitates clear-cell renal cell carcinoma aerobic glycolysis
por: Yuan, Bao, et al.
Publicado: (2023)

RNA N6-methyladenosine reader IGF2BP3 promotes acute myeloid leukemia progression by controlling stabilization of EPOR mRNA
por: Fan, Jin, et al.
Publicado: (2023)

N6-methyladenosine methylation in kidney injury
por: Wang, Qimeng, et al.
Publicado: (2023)

N(6)-methyladenosine (m(6)A) methyltransferase METTL3 regulates sepsis-induced myocardial injury through IGF2BP1/HDAC4 dependent manner
por: Shen, Hao, et al.
Publicado: (2022)

IGF2BP3 promotes cell metastasis and is associated with poor patient survival in nasopharyngeal carcinoma
por: Xu, Yun, et al.
Publicado: (2021)

N6-Methyladenosine Methyltransferase METTL3 Promotes Angiogenesis and Atherosclerosis by Upregulating the JAK2/STAT3 Pathway via m6A Reader IGF2BP1
por: Dong, Guo, et al.
Publicado: (2021)

PRMT3-mediated arginine methylation of IGF2BP1 promotes oxaliplatin resistance in liver cancer
por: Shi, Yunxing, et al.
Publicado: (2023)

The YTH Domain Family of N6-Methyladenosine “Readers” in the Diagnosis and Prognosis of Colonic Adenocarcinoma
por: Xu, Dian, et al.
Publicado: (2020)

RNA-Binding Protein IGF2BP1 Associated With Prognosis and Immunotherapy Response in Lung Adenocarcinoma
por: Liu, JinFeng, et al.
Publicado: (2022)

4E-BP1(Thr46) Phosphorylation Association with Poor Prognosis in Quantitative Phosphoproteomics of Portal Vein Tumor Thrombus Revealed that 4E-BP1Thr46 Phosphorylation is Associated with Poor Prognosis in HCC
por: Lin, Xincong, et al.
Publicado: (2020)

Effects of RNA methylation N6-methyladenosine regulators on malignant progression and prognosis of melanoma
por: Liu, Jinfang, et al.
Publicado: (2021)

Immune infiltration-related N6-methyladenosine RNA methylation regulators influence the malignancy and prognosis of endometrial cancer
por: Ma, Jian, et al.
Publicado: (2021)

IGF2BP3 Regulates TMA7-mediated Autophagy and Cisplatin Resistance in Laryngeal Cancer via m6A RNA Methylation
por: Yang, Like, et al.
Publicado: (2023)

ITGB3BP is a potential biomarker associated with poor prognosis of glioma
por: Liu, Zhendong, et al.
Publicado: (2021)

Expression of the cancer testis antigen IGF2BP3 in colorectal cancers; IGF2BP3 holds promise as a specific immunotherapy target
por: Shantha Kumara, HMC, et al.
Publicado: (2015)

MNSFβ regulates placental development by conjugating IGF2BP2 to enhance trophoblast cell invasiveness
por: Yang, Qian, et al.
Publicado: (2021)

CtBP2 overexpression promotes tumor cell proliferation and invasion in gastric cancer and is associated with poor prognosis
por: Dai, Faxiang, et al.
Publicado: (2017)

Abnormal methylation characteristics predict chemoresistance and poor prognosis in advanced high-grade serous ovarian cancer
por: Feng, Li-yuan, et al.
Publicado: (2021)

Effect of N6-methyladenosine methylation-related gene signature for predicting the prognosis of hepatocellular carcinoma patients
por: Zheng, Xinyu, et al.
Publicado: (2023)

Role of IGF2BP3 in trophoblast cell invasion and migration
por: Li, W, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_6ls3gmm3eke4g7s6fdci1aim7n